Company intelligence / Profile preview
Medinno, Inc.
Seoul, South Koreamedinno.kr ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Medinno's flagship product HIEstem™ has completed Phase 1 clinical trial for Neonatal Hypoxic Ischemic Encephalopathy (HIE) and Intraventricular Hemorrhage (IVH), with Orphan Drug Designation in South Korea and Rare Pediatric Disease Designation in the US; preparing for global Phase 2.[1]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Neural stem cell therapyMesenchymal stem cell therapyStem cell therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Cytonus Therapeutics (license for HIEstem™ in North America and MENA)
Beyond the preview
Go deeper on Medinno, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medinno, Inc..